[1]张凯新,杨林瀛.不同嗜酸性粒细胞水平的慢性阻塞性肺疾病急性加重期患者临床分析[J].医学信息,2021,34(08):85-88.[doi:10.3969/j.issn.1006-1959.2021.08.022]
　ZHANG Kai-xin,YANG Lin-ying.Clinical Analysis of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Different Levels of Eosinophils[J].Medical Information,2021,34(08):85-88.[doi:10.3969/j.issn.1006-1959.2021.08.022]
点击复制

不同嗜酸性粒细胞水平的慢性阻塞性肺疾病急性加重期患者临床分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年08期
页码:
85-88
栏目:
论著
出版日期:
2021-04-15

文章信息/Info

Title:
Clinical Analysis of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Different Levels of Eosinophils
文章编号:
1006-1959（2021）08-0085-04
作者:
张凯新; 杨林瀛
（1.承德医学院研究生院，河北 承德 067000； 2.承德医学院附属医院呼吸与危重症医学科，河北 承德 067000）
Author(s):
ZHANG Kai-xin; YANG Lin-ying
(1.Graduate School of Chengde Medical University,Chengde 067000,Hebei,China; 2.Department of Respiratory and Critical Care Medicine,Affiliated Hospital of Chengde Medical University, Chengde 067000,Hebei,China)
关键词:
嗜酸性粒细胞; 慢性阻塞性肺疾病; WBC; NLR; PCT
Keywords:
Eosinophils; Chronic obstructive pulmonary disease; WBC; NLR; PCT
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2021.08.022
文献标志码:
A
摘要:
目的 分析外周血不同嗜酸性粒细胞（EOS）水平慢性阻塞性肺疾病急性加重期患者的临床特点，探讨外周血EOS对指导慢阻肺急性加重期患者病情评估、治疗、预后等方面的价值。方法 回顾性分析2019年6月~2020年6月本院收治的135例慢阻肺急性加重患者，依据患者外周血EOS水平将其分为组Ⅰ（n=53）和组Ⅱ（n=82）。比较两组患者的一般资料（性别、年龄、吸烟史、慢阻肺病程、合并症、全身激素使用情况）；白细胞计数（WBC）、中性粒细胞/淋巴细胞（NLR）、降钙素原（PCT）、纤维蛋白原（FIB）、痰培养阳性率；氧合指数；机械通气率、住院天数、治疗效果。结果 两组患者性别、年龄、吸烟史、慢阻肺病程、合并症、全身激素使用情况等一般资料比较，差异无统计学意义(P＞0.05)；入院时组ⅡWBC、NLR、PCT、FIB高于组Ⅰ，差异有统计学意义(P＜0.05)，两组痰培养阳性率比较，差异无统计学意义(P＞0.05)；组Ⅱ氧合指数低于组Ⅰ，差异有统计学意义(P＜0.05)；组Ⅱ机械通气率、住院天数高于组Ⅰ，治疗好转率低于组Ⅰ，差异有统计学意义（P＜0.05）。结论 外周血EOS水平对评估慢阻肺急性加重期患者病情、指导治疗、临床预后具有一定的参考价值。
Abstract:
Objective To analyze the clinical characteristics of patients with different levels of eosinophils (EOS) in peripheral blood in patients with acute exacerbation of chronic obstructive pulmonary disease, and to explore the value of peripheral blood EOS in guiding the evaluation, treatment, and prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease.Methods A retrospective analysis of 135 patients with acute exacerbation of chronic obstructive pulmonary disease admitted to our hospital from June 2019 to June 2020.According to the EOS level in the peripheral blood of patients, they were divided into group Ⅰ (n=53) and group Ⅱ(n=82).Compare the general information of the two groups of patients (gender, age, smoking history, chronic obstructive pulmonary disease course, comorbidities, systemic hormone use);White blood cell count (WBC), neutrophils/lymphocytes (NLR), procalcitonin (PCT), fibrinogen (FIB), positive rate of sputum culture; oxygenation index; mechanical ventilation rate, hospitalization days, treatment effect.Results There was no statistically significant difference between the two groups of patients in general data such as gender, age, smoking history, chronic obstructive pulmonary disease course, comorbidities, and systemic hormone usage (P＞0.05);WBC, NLR, PCT and FIB in group Ⅱ were higher than those in group Ⅰ at the time of admission, the difference was statistically significant (P＜0.05).There was no significant difference in the positive rate of sputum culture between the two groups (P＞0.05);The oxygenation index of group Ⅱ was lower than that of group Ⅰ, the difference was statistically significant (P＜0.05);The rate of mechanical ventilation and the length of hospital stay in group Ⅱ were higher than those in group Ⅰ, and the treatment improvement rate was lower than that in group Ⅰ,the difference was statistically significant (P＜0.05).Conclusion The level of EOS in peripheral blood has certain reference value for evaluating the condition of patients with acute exacerbation of chronic obstructive pulmonary disease, guiding treatment, and clinical prognosis.

参考文献/References:

[1]Wang C,Xu J,Yang L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH]study):a National cross-sectional study[J].Lancet,2018,391(1131):1706-1717. [2]Vogelmeier CF,criner GJ,Martinez FJ,et al.Global Strategy for the Diagnosis,Management,and Prevention of Chronic Obstructive Lung Disease 2017 Report[J].Am J Repir Crit Care Med,2017,195(5):557-582. [3]Fabbri LM,Hurd SS.Global Strategy for the Diagnosis,Management and Prevention of COPD:2003 update[J].European Respiratory Journal,2003,22(1):1-2. [4]张莹莹,李娜苗,范亚莉,等.外周血嗜酸性粒细胞水平对AECOPD患者预后的评估价值[J].陕西医学杂志,2018,47(5):561-563. [5]彭樱.伴有外周血嗜酸性粒细胞增多的慢性阻塞性肺病急性加重患者的临床特征分析[D].苏州大学,2017. [6]Global Initiative for Chronic Obstructive Lung Disease.Global Strategy for the Diagnosis,Management and Prevention of COPD[EB/OL].[2019-02-15].https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-preventioncopd/. [7]李文学,鱼光玲.慢性阻塞性肺疾病急性加重期住院患者临床转归相关性分析[J].中国继续医学教育,2017,9(35):36-38. [8]王莹莹,郝兴亮,冯涛,等.痰嗜酸性粒细胞评估糖皮质激素治疗AECOPD的疗效价值[J].临床药物治疗杂志,2017,15(7):22-25. [9]柳威,陈荣昌.慢性阻塞性肺疾病诱导痰细胞分类特点及其与治疗反应性的相关性分析[J].中国呼吸与危重监护杂志,2016,15(6):537-541. [10]李振华,张华.嗜酸性粒细胞计数与呼出气一氧化氮浓度在慢性阻塞性肺疾病中的应用[J].临床医药实践,2018,27(7):498-501. [11]Negewo NA,McDonald VM,Baines KJ,et al.Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD[J].Int J Chron Obstruct Pulmon Dis,2016(11):1495-1504. [12]王景,陈碧,朱述阳.入院时外周血嗜酸粒细胞百分比与慢性阻塞性肺疾病急性加重患者出院后短期内急性加重复发的关系研究[J].实用心脑肺血管病杂志,2019,27(7):46-50. [13]杨宏宽,张艳,张佳颖,等.哮喘-慢性阻塞性肺疾病重叠患者中痰髓过氧化物酶、嗜酸粒细胞阳离子蛋白与临床特征的相关性[J].南方医科大学学报,2018,38(10):71-77. [14]Bafadhel M,Greening NJ,Harvey-Dunstan TC,et al.Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD[J].Chest,2016,150(2):320-328. [15]Landis S,Suruki R,Maskell J,et al.Demographic and clinical characteristics of COPD patients at different blood eosinophil levels in the UK Clinical Practice Research Datalink[J].COPD,2018,15(2):177-184. [16]郑春明,李论,黄克武.外周血嗜酸性粒细胞与慢性阻塞性肺疾病急性加重期住院患者临床转归的相关性分析[J].中国临床医生杂志,2016,44(10):42-44. [17]刘志刚.探讨血清嗜酸性粒细胞计数与慢性阻塞性肺疾病急性加重期的关系[J].中国医学工程,2017,25(3):46-48. [18]杨艳珍.外周血嗜酸性粒细胞不同的分类方法与AECOPD临床特征及预后的相关分析[D].山西医科大学,2020. [19]Schuetz P,Wirz Y,Sager R,et al.Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis[J].Lancet Infect Dis,2018,18(1):95-107. [20]Patel A,Szydlo RM,Auner HW,et al.C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early- and long-term mortality[J].Br J Haematol,2016,42(2):43-234. [21]刘瑶瑶.NLR在慢性阻塞性肺疾病中的价值[D].昆明医科大学,2020. [22]杨伟.探讨炎症性肠病中凝血异常与炎症反应的关系[J].中国卫生标准管理,2015,6(6):165-166. [23]Fermont JM,Masconi KL,Jensen MT,et al.Biomarkers and clinical outcomes in COPD:a systematic review and meta-analysis[J].Thorax,2019,74(5):439-446. [24]金丛,黄相增.凝血纤溶指标及动脉血气在AECOPD合并肺动脉高压中的相关性研究[J].临床肺科杂志,2015,2(2):276-279. [25]Kim TH,Oh DK,Oh YM,et al.Fibrinogen as a potential biomarker for clinical phenotype in patients with chronic obstructive pulmonary disease[J].J Thorac Dis,2018,10(9):5260-5268. [26]王慧,杨华,陈卓昌.外周血嗜酸性粒细胞对慢性阻塞性肺疾病急性加重激素治疗相关性分析[J].河南医学高等专科学校学报,2020,32(2):130-133. [27]Lopez-campos JL.Heterogeneity of chronic obstructive pulmonary disease exacerbations:a two-axes classification proposal[J].The Lancet Respiratory Medicine,2015,3(9):729-734 [28]李希,谭双香,胡瑞成,等.慢性阻塞性肺疾病合并焦虑/抑郁的相关因素[J].国际病理科学与临床杂志,2019,39(2):307-313. [29]Kang HS,Rhee CK,Kim SK,et al.Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD[J].Int J Chron Obstruct Pulmon Dis,2016(11):2467-2473. [30]崔雨佳,刘忠.外周血嗜酸性粒细胞水平与慢性阻塞性肺疾病急性加重期患者临床预后的相关性分析[J].现代检验医学杂志,2020,35(3):129-132,164. [31]曹娟.血嗜酸性粒细胞在慢性阻塞性肺疾病急性加重期住院治疗中的作用[J].临床肺科杂志,2018,23(6):1115-1117. [32]袁玉屏,王蒨,刘伟春,等.嗜酸粒细胞水平对急性加重期慢性阻塞性肺疾病患者治疗效果与生存状况的影响[J].当代医学,2019,25(18):93-96.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(08):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(08):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Medical Information,2018,31(08):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(08):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Medical Information,2018,31(08):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(08):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Medical Information,2018,31(08):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(08):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
　ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
[11]于易琼,李 秀.血嗜酸性粒细胞及血尿酸在频繁急性加重表型慢性阻塞性肺疾病患者中的表达特征[J].医学信息,2022,35(02):6.[doi:10.3969/j.issn.1006-1959.2022.02.002]
　YU Yi-qiong,LI Xiu.Expression Characteristics of Blood Eosinophils and Serum Uric Acid in Patientswith Frequent Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(08):6.[doi:10.3969/j.issn.1006-1959.2022.02.002]
[12]刘霖杰,袁晓梅.嗜酸性粒细胞在慢性阻塞性肺疾病中的研究现状[J].医学信息,2023,36(18):179.[doi:10.3969/j.issn.1006-1959.2023.18.037]
　LIU Lin-jie,YUAN Xiao-mei.Research Status of Eosinophils in Chronic Obstructive Pulmonary Disease[J].Medical Information,2023,36(08):179.[doi:10.3969/j.issn.1006-1959.2023.18.037]

更新日期/Last Update: 1900-01-01